一名系统性红斑狼疮患者在接受抗瘤单抗和霉酚酸酯治疗两年内发生弥漫性大B细胞淋巴瘤。

IF 1 4区医学 Q3 MEDICINE, GENERAL & INTERNAL

Internal Medicine Pub Date : 2025-04-12 DOI:10.2169/internalmedicine.5362-25

Takuya Matsubara, Masahiro Takita, Ikue Sekai, Naoya Omaru, Natsuki Okai, Masahiro Morita, Ken Kamata, Kosuke Minaga, Tomohiro Watanabe, Masatoshi Kudo

{"title":"一名系统性红斑狼疮患者在接受抗瘤单抗和霉酚酸酯治疗两年内发生弥漫性大B细胞淋巴瘤。","authors":"Takuya Matsubara, Masahiro Takita, Ikue Sekai, Naoya Omaru, Natsuki Okai, Masahiro Morita, Ken Kamata, Kosuke Minaga, Tomohiro Watanabe, Masatoshi Kudo","doi":"10.2169/internalmedicine.5362-25","DOIUrl":null,"url":null,"abstract":"Anifrolumab is a newly developed biological agent for patients with moderate-to-severe systemic lupus erythematosus (SLE). Anifrolumab neutralizes the signaling pathways mediated by type I interferons (IFNs), which are involved in viral clearance and anticancer immunity. Although susceptibility to viral infections has been reported in patients treated with anifrolumab, whether anifrolumab treatment increases the cancer risk in patients with SLE is unknown. We herin report a case of SLE that manifested as aggressive diffuse large B-cell lymphoma (DLBCL) after treatment with anifrolumab. The neutralization of type I IFNs by anifrolumab may promote the development of DLBCL owing to defective anticancer immunity.","PeriodicalId":13719,"journal":{"name":"Internal Medicine","volume":" ","pages":""},"PeriodicalIF":1.0000,"publicationDate":"2025-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Development of Diffuse Large B Cell Lymphoma in a Patient with Systemic Lupus Erythematosus within Two Years after the Initiation of Anifrolumab and Mycophenolate Mofetil Treatment.\",\"authors\":\"Takuya Matsubara, Masahiro Takita, Ikue Sekai, Naoya Omaru, Natsuki Okai, Masahiro Morita, Ken Kamata, Kosuke Minaga, Tomohiro Watanabe, Masatoshi Kudo\",\"doi\":\"10.2169/internalmedicine.5362-25\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Anifrolumab is a newly developed biological agent for patients with moderate-to-severe systemic lupus erythematosus (SLE). Anifrolumab neutralizes the signaling pathways mediated by type I interferons (IFNs), which are involved in viral clearance and anticancer immunity. Although susceptibility to viral infections has been reported in patients treated with anifrolumab, whether anifrolumab treatment increases the cancer risk in patients with SLE is unknown. We herin report a case of SLE that manifested as aggressive diffuse large B-cell lymphoma (DLBCL) after treatment with anifrolumab. The neutralization of type I IFNs by anifrolumab may promote the development of DLBCL owing to defective anticancer immunity.\",\"PeriodicalId\":13719,\"journal\":{\"name\":\"Internal Medicine\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.0000,\"publicationDate\":\"2025-04-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Internal Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2169/internalmedicine.5362-25\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Internal Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2169/internalmedicine.5362-25","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

摘要

Anifrolumab是一种新开发的用于中重度系统性红斑狼疮（SLE）患者的生物制剂。Anifrolumab中和I型干扰素（ifn）介导的信号通路，ifn参与病毒清除和抗癌免疫。尽管有报道称接受anfrolumab治疗的患者对病毒感染易感性，但anfrolumab治疗是否会增加SLE患者的癌症风险尚不清楚。我们在此报告一例系统性红斑狼疮，在接受anifrolumab治疗后表现为侵袭性弥漫性大b细胞淋巴瘤（DLBCL）。anfrolumab对I型ifn的中和可能由于抗癌免疫缺陷而促进DLBCL的发展。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Development of Diffuse Large B Cell Lymphoma in a Patient with Systemic Lupus Erythematosus within Two Years after the Initiation of Anifrolumab and Mycophenolate Mofetil Treatment.

Anifrolumab is a newly developed biological agent for patients with moderate-to-severe systemic lupus erythematosus (SLE). Anifrolumab neutralizes the signaling pathways mediated by type I interferons (IFNs), which are involved in viral clearance and anticancer immunity. Although susceptibility to viral infections has been reported in patients treated with anifrolumab, whether anifrolumab treatment increases the cancer risk in patients with SLE is unknown. We herin report a case of SLE that manifested as aggressive diffuse large B-cell lymphoma (DLBCL) after treatment with anifrolumab. The neutralization of type I IFNs by anifrolumab may promote the development of DLBCL owing to defective anticancer immunity.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Internal Medicine 医学-医学：内科

CiteScore

1.90

自引率

8.30%

发文量

审稿时长

2.2 months

期刊介绍： Internal Medicine is an open-access online only journal published monthly by the Japanese Society of Internal Medicine. Articles must be prepared in accordance with "The Uniform Requirements for Manuscripts Submitted to Biomedical Journals (see Annals of Internal Medicine 108: 258-265, 1988), must be contributed solely to the Internal Medicine, and become the property of the Japanese Society of Internal Medicine. Statements contained therein are the responsibility of the author(s). The Society reserves copyright and renewal on all published material and such material may not be reproduced in any form without the written permission of the Society.